Preliminary net revenue increased 73% to $72.5 million for Q1 2025, compared to $41.9 million in Q1 2024 Achieved preliminary GAAP net income of $4.5 million, or $0.27 per share Reported preliminary ...
Company reports transformative second-quarter revenue, contributing to a record total of $116.4 million in revenue for the first half of 2024 AmnioWrap2 continues to be a major growth driver achieving ...
Miami, Florida--(Newsfile Corp. - July 16, 2024) - Innovation is the lifeblood of the MedTech sector. Literally. Discoveries made are more than value drivers for the companies behind them; they can be ...
POMPANO BEACH, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (the “Company” or “BioStem”), a leading MedTech company focused on the development, manufacture, and ...
POMPANO BEACH, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization ...
POMPANO BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal ...
POMPANO BEACH, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of ...
Generated net revenue of $10.1 million for the fourth quarter 2025 and gross margin of 97% Completed the acquisition of the BioTissue Holdings Inc. surgical and wound assets in January 2026, ...
"BioStem delivered a solid finish to 2025, with fourth quarter revenue reflecting continued penetration of the physician office market,” said Jason Matuszewski, CEO and Chairman of the Board of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results